Everest Group, Ltd.
Case Overview
42 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline:12/28/2026 |
| Status: | Status:Investigating |
| Company Name: | Company Name:Everest Group, Ltd. |
| Court: | Court:Southern District of New York |
| Case Number: | Case Number:1:26cv09448 |
| Class Period: | Class Period:02/08/2024 - 10/27/2025 |
| Ticker: | Ticker:EG |
| Related Attorneys: | Lead Attorneys:Thomas W. Elrod |
| Related Practices: | Related Practices:Securities |
The lawsuit alleges that Everest made false and/or misleading statements and failed to disclose that: (i) Everest remained materially exposed to and concentrated in casualty risks subject to escalating claim costs, including business the Company claimed Everest had reduced or exited; (ii) Everest had inadequately priced portions of that business; (iii) Everest’s reserves were insufficient, causing it to understate its liabilities and expenses and materially overstate its earnings; and (iv) addressing these problems would require substantial reserve charges, protection against further adverse development, and reductions in Everest’s casualty business, thereby sacrificing recurring premium revenue.
On October 30, 2024, Everest released its third quarter 2024 financial results, revealing that loss activity in its U.S. casualty business had “definitely spiked” and that rate increases had accelerated into the high teens. Management stated it was becoming “increasingly cautious” and declining to renew underperforming accounts. On this news, the price of Everest shares declined by $24.39 per share, or approximately 6.4%, from $380.00 per share on October 30, 2024 to close at $355.61 on October 31, 2024.
Then, on December 3, 2024, Everest disclosed that Michael Karmelowivz had resigned as Chairman of Everest Global Insurance, effective immediately. On this news, the price of Everest shares declined by $6.44 per share, or approximately 1.7%, from $385.21 per share on December 3, 2024 to close at $378.77 on December 4, 2024.
On December 4, 2024, Wells Fargo lowered its price target and 2024 earnings estimate based on its projection that Everest could record an $872 million reserve increase related to U.S. casualty lines in the Company’s Insurance segment, stating that “the recent resignation of Mike Karmilowicz as Head of Insurance we believe also flags there could be a larger charge coming.” On this news, Everest shares declined by $4.06 per share, or approximately 1.1%, from $378.77 per share on December 4, 2024 to close at $374.71 on December 5, 2024.
Then, on January 8, 2025, Everest announced that the Company’s Chief Executive Officer, Juan Andrade, would be departing the company and James Williamson had been appointed as the new CEO. On this news, the price of Everest shares declined by $14.91 per share, or approximately 4.1%, from $368.41 per share on January 8, 2025 to close at $353.52 on January 10, 2025.
Finally, On October 27, 2025, Everest disclosed that it had recorded $478 million in net unfavorable prior year reserve development, driven principally by adverse development in U.S. casualty losses from accident years 2022 through 2024. The Company also announced it had purchased up to $1.2 billion of adverse development protection from Longtail Re on approximately $5.4 billion of North American Insurance and Other segment reserves for accident years 2024 and prior. On this news, the price of Everest shares declined by $39.07 per share, or approximately 11.4%, from $343.98 per share on October 27, 2025 to close at $304.91 on October 28, 2025.
On October 30, 2024, Everest released its third quarter 2024 financial results, revealing that loss activity in its U.S. casualty business had “definitely spiked” and that rate increases had accelerated into the high teens. Management stated it was becoming “increasingly cautious” and declining to renew underperforming accounts. On this news, the price of Everest shares declined by $24.39 per share, or approximately 6.4%, from $380.00 per share on October 30, 2024 to close at $355.61 on October 31, 2024.
Then, on December 3, 2024, Everest disclosed that Michael Karmelowivz had resigned as Chairman of Everest Global Insurance, effective immediately. On this news, the price of Everest shares declined by $6.44 per share, or approximately 1.7%, from $385.21 per share on December 3, 2024 to close at $378.77 on December 4, 2024.
On December 4, 2024, Wells Fargo lowered its price target and 2024 earnings estimate based on its projection that Everest could record an $872 million reserve increase related to U.S. casualty lines in the Company’s Insurance segment, stating that “the recent resignation of Mike Karmilowicz as Head of Insurance we believe also flags there could be a larger charge coming.” On this news, Everest shares declined by $4.06 per share, or approximately 1.1%, from $378.77 per share on December 4, 2024 to close at $374.71 on December 5, 2024.
Then, on January 8, 2025, Everest announced that the Company’s Chief Executive Officer, Juan Andrade, would be departing the company and James Williamson had been appointed as the new CEO. On this news, the price of Everest shares declined by $14.91 per share, or approximately 4.1%, from $368.41 per share on January 8, 2025 to close at $353.52 on January 10, 2025.
Finally, On October 27, 2025, Everest disclosed that it had recorded $478 million in net unfavorable prior year reserve development, driven principally by adverse development in U.S. casualty losses from accident years 2022 through 2024. The Company also announced it had purchased up to $1.2 billion of adverse development protection from Longtail Re on approximately $5.4 billion of North American Insurance and Other segment reserves for accident years 2024 and prior. On this news, the price of Everest shares declined by $39.07 per share, or approximately 11.4%, from $343.98 per share on October 27, 2025 to close at $304.91 on October 28, 2025.